Comparative Pharmacokinetic and Pharmacodynamic Profile of Piperacillin/Tazobactam 3.375G Q4H and 4.5G Q6H

  title={Comparative Pharmacokinetic and Pharmacodynamic Profile of Piperacillin/Tazobactam 3.375G Q4H and 4.5G Q6H},
  author={Holly M. Mattoes and Blair Capitano and Myo-Kyoung Kim and Dawei Xuan and Richard Quintiliani and Charles H. Nightingale and David P. Nicolau},
  pages={59 - 63}
When piperacillin/tazobactam has been used to treat hospitalized patients with serious infections, including nosocomial pneumonia caused by Pseudomonas aeruginosa, it has usually been dosed at 3.375 g q4h to provide serum concentrations above commonly encountered organisms’ MICs (T > MIC) for at least 40–50% of the dosing interval. Pharmacodynamic principles suggest that a similar efficacy can be realized with extended dosing intervals when a larger dose (e.g. 4.5 g q6h) is administered, which… 

Figures and Tables from this paper

Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation

It is indicated that piperacillin-tazobactam should have utility for empirical therapy of hospital-onset infections.

Pharmacokinetics of piperacillin/tazobactam in cancer patients with hematological malignancies and febrile neutropenia after chemotherapy

Patients with FN after receiving chemotherapy exhibited significant variations in the pharmacokinetic parameters of piperacillin compared with healthy individuals; specifically, FN patients demonstrated an increase in t1/2 and decreased CL.

Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients

In critically ill patients, therapeutic monitoring must be part of the routine, and knowledge of ClCR value may be useful for the choice of adequate initial piperacillin dosing, as well as for patients with higher ClCR values.

In Vivo Comparison of CXA-101 (FR264205) with and without Tazobactam versus Piperacillin-Tazobactam Using Human Simulated Exposures against Phenotypically Diverse Gram-Negative Organisms

Overall, human simulated exposures of CXA-101 with or without tazobactam demonstrated improved efficacy versus piperacillin-tazobactsam, and the inhibitor combinations showed enhanced CFU decreases versus CXa-101 alone.

Determination of Nontoxic Concentrations of Piperacillin/Tazobactam for Intravitreal Application

Piperacillin/tazobactam is the highest nontoxic dose to the normal retinas of adult albino rabbits as intravitreal injection and may be a new, potentially important drug in the treatment of endophthalmitis as it has a broad antimicrobial spectrum.

Pharmacokinetic and Pharmacodynamic Evaluation of Two Dosing Regimens for Piperacillin‐Tazobactam

The pharmacokinetic and pharmacodynamic profiles of two dosing regimens for piperacillin‐tazobactam against commonly encountered pathogens were compared to establish a baseline for comparison in clinical practice.

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli

Despite phenotypically and genotypically defined resistance, TZP displayed efficacy against these E. coli strains that are pan-β-lactam susceptible but piperacillin-tazobactam resistant (TZP-R) in vitro.

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Klebsiella pneumoniae Strains

Assessment of the efficacy of a humanized exposure of piperacillin-tazobactam (TZP) against 12 TZP-R/PBL-S K. pneumoniae isolates in an immunocompromised murine lung infection model found Discordance between the in vitro resistance profile and the in vivo efficacy of human-simulated TZPs observed.



Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens

Inhibitory and bactericidal activities for the two regimens were determined with five American Type Culture Collection (ATCC) organisms (Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Bacteroides fragilis) and predicted measures of bactericidal and inhibitory activity were compared with measured AUBC0-24 and AUIC0- 24 values.

Rational Prescribing of Extended-Spectrum Penicillin β-Lactamase Inhibitor Combinations: Focus on Ticarcillin/Clavulanic Acid

  • M. Reed
  • Medicine, Biology
    The Annals of pharmacotherapy
  • 1998
Integration of pharmacokinetic and pharmacodynamic data is an appropriate means to assess/reassess dosing recommendations for antimicrobial agents.

Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis.

Single agent therapy has the advantage of providing reliable serum concentrations and, in contrast to the standard therapy, does not necessitate monitoring of serum drug concentrations.

Comparison of the bactericidal activities of piperacillin-tazobactam, ticarcillin-clavulanate, and ampicillin-sulbactam against clinical isolates of Bacteroides fragilis, Enterococcus faecalis, Escherichia coli, and Pseudomonas aeruginosa

The data suggest that use of shorter dosing intervals or continuous-infusion regimens should be considered in combination with an aminoglycoside to improve the bactericidal profiles of these agents for E. faecalis and P. aeruginosa.

Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models.

This paper evaluated the impact of dosing interval on the relative efficacy and potency of beta-lactams, aminoglycosides, and ciprofloxacin against Pseudomonas aeruginosa in murine pneumonitis and thigh-infection models.

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.

Compared the relative efficacy and potency of three beta-lactams and two aminoglycosides in lung and thigh-infection models in neutropenic mice by defining the maximum attainable antimicrobial effect at 24 h (Emax) and the total dose required to reach 50% of maximum effect (P50) at several dosing intervals.

Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.

Because of the rapid development of imipenem resistance despite combination therapy, the high proportion of side effects, and the risk of induction of beta-lactam resistance, imipanem/cilastatin cannot be recommended for routine treatment of CF-patients with P. aeruginosa infection.

Interactions of antimicrobial combinations in vitro: the relativity of synergism.

  • J. Blaser
  • Biology, Medicine
    Scandinavian journal of infectious diseases. Supplementum
  • 1990
The observed discrepancies between standard methods for testing drug interaction and a model which more closely reflects human pharmacokinetics support the argument that standard synergy testing provides incomplete data to reliably design clinical combination therapy.